To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Home / DHHS Recommendation Could See New Era in Cannabis Advertising
DHHS Recommendation Could See New Era in Cannabis Advertising
As the global cannabis industry continues to absorb what a potential US rescheduling of cannabis would mean for its future, VDX.tv’s Director of Client Partnerships for CBD, Lauren White, explained to Business of Cannabis why this could ‘enable cannabis companies to step out of the shadows and establish themselves in the mainstream market’.
Emerging Avenues in Advertising for Cannabis
The US Department of Health and Human Services has recommended reclassifying marijuana as a lower-risk drug, which would in turn ease restrictions. While this new Schedule III recommendation holds a myriad of implications including banking and tax codes, a standout beneficiary will be the domain of advertising. With barriers lifting, advertising platforms and strategies for cannabis (and CBD) enterprises are set to revolutionise.
As federal restrictions around this category ease, the media world, once apprehensive about cannabis advertising, should see a renaissance. Previously off-limits platforms will likely open up, enabling cannabis companies to step out of the shadows and establish themselves in the mainstream market.
A few reasons why it will be crucial for CBD and cannabis brands to work with reputable adtech partners that are versed in this industry:
In essence, the cannabis industry stands at the cusp of an advertising revolution. As the barriers slowly fall away (or show promising momentum that direction), brands have an unprecedented opportunity to redefine their public persona and bring in new customers.
Ben Stevens
Other featured articles
Bring It On: Meet the Cannabis CMO Welcoming Scrutiny With Open Arms
By
The Right Reforms, the Wrong Narrative: Why the Medical Cannabis Debate Is Missing Half the Picture
By
Five Years, 74 Patients: Ireland Moves Forward With Review of Its Failing Medical Cannabis Programme
By
CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited
By
Is the ‘Commercial Scale’ of Medical Cannabis in the UK Inappropriate?
By
Other featured Opinion articles
Is the ‘Commercial Scale’ of Medical Cannabis in the UK Inappropriate?
By
Is a Cannabis M&A Tidal Wave on the Way?
By
Rescheduling Will Reprice Medical IP, Not Retail Footprints
By
Organigram Acquires Sanity Group: When Big Tobacco Moves into Cannabis
By
US Cannabis Rescheduling: A Victory or a Federal Trap?
By
Share Article
Related news
Bring It On: Meet the Cannabis CMO Welcoming Scrutiny With Open Arms
By
The Right Reforms, the Wrong Narrative: Why the Medical Cannabis Debate Is Missing Half the Picture
By
Five Years, 74 Patients: Ireland Moves Forward With Review of Its Failing Medical Cannabis Programme
By
CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited
By
Is the ‘Commercial Scale’ of Medical Cannabis in the UK Inappropriate?
By
Züri Can Extended By Two Years As Results Point To Black Market Deterrence
By
Oliver’s Law: The Campaign That Could Reshape UK Cannabis Prescribing
By
Has UK’s ‘Brexit Reset’ Derailed 5-Year CBD Approval Battle?
By
‘How Does the DEA Plan to Reschedule Without a Judge?’ – Lawmaker Demands Answers on Cannabis Rescheduling Chaos
By